Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Pharvaris ( (PHVS) ) is now available.
On June 27, 2025, Pharvaris N.V. held its Annual General Meeting of Shareholders, where key resolutions were passed. Shareholders adopted the Dutch statutory annual accounts for 2024, appointed PricewaterhouseCoopers as the auditor for 2025, and discharged directors from liability for 2024. Additionally, the board’s authorization to acquire shares was extended, and Dr. Meeker, Dr. Glassman, and Ms. Monges were re-appointed as non-executive directors. These decisions reflect the company’s commitment to maintaining strong governance and financial oversight, potentially bolstering stakeholder confidence.
The most recent analyst rating on (PHVS) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Pharvaris stock, see the PHVS Stock Forecast page.
Spark’s Take on PHVS Stock
According to Spark, TipRanks’ AI Analyst, PHVS is a Neutral.
Pharvaris exhibits significant financial difficulties, with no revenue and ongoing losses, resulting in a low financial performance score. Despite some technical momentum, the valuation is poor due to negative earnings. The stock’s overall score is affected by these financial and valuation challenges, despite its technical strength.
To see Spark’s full report on PHVS stock, click here.
More about Pharvaris
Pharvaris N.V. operates in the pharmaceutical industry, focusing on the development of innovative therapies for rare diseases. The company is primarily engaged in creating oral treatments for hereditary angioedema, a condition characterized by severe swelling attacks.
Average Trading Volume: 69,187
Technical Sentiment Signal: Buy
Current Market Cap: $956.9M
Learn more about PHVS stock on TipRanks’ Stock Analysis page.